Understanding PLZF: Two transcriptional targets, REDD1 and smooth muscle α-actin, define new questions in growth control, senescence, self-renewal and tumor suppression

Cell Cycle

Volumn 10, Issue 5, 2011, Pages 771-775

  Kolesnichenko, Marina ^a   Vogt, Peter K ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Cytoskeleton; Oncogenic transformation; Pluripotency; Senescence; Spermatogonial progenitors

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; PROTEIN; PROTEIN PROMYELOCYTIC LEUKEMIA ZINC FINGER; PROTEIN REDD1; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

CANCER INHIBITION; CELL GROWTH; CELL RENEWAL; GROWTH REGULATION; NONHUMAN; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SENESCENCE; TRANSCRIPTION REGULATION;

EID: 79952351589     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.5.14829     Document Type: Review

References (58)

1. McConnell MJ, Licht JD. The PLZF gene of t(11;17)-associated APL. Curr Top Microbiol Immunol 2007; 313:31-48. (Pubitemid 47400331)
2. Chen Z, Brand NJ, Chen A, Chen SJ, Tong JH, Wang ZY, et al. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J 1993; 12:1161-7. (Pubitemid 23095865)
3. Scaglioni PP, Pandolfi PP. The theory of APL revisited. Curr Top Microbiol Immunol 2007; 313:85-100. (Pubitemid 47400334)
4. Doulatov S, Notta F, Rice KL, Howell L, Zelent A, Licht JD, et al. PLZF is a regulator of homeostatic and cytokine-induced myeloid development. Genes Dev 2009; 23:2076-87.
5. Xu D, Holko M, Sadler AJ, Scott B, Higashiyama S, Berkofsky-Fessler W, et al. Promyelocytic leukemia zinc finger protein regulates interferon-mediated innate immunity. Immunity 2009; 30:802-16.
6. Labbaye C, Quaranta MT, Pagliuca A, Militi S, Licht JD, Testa U, et al. PLZF induces megakaryocytic development, activates Tpo receptor expression and interacts with GATA1 protein. Oncogene 2002; 21:6669-79. (Pubitemid 35177046)
7. Dick JE, Doulatov S. The role of PLZF in human myeloid development. Ann NY Acad Sci 2009; 1176:150-3.
8. Savage AK, Constantinides MG, Han J, Picard D, Martin E, Li B, et al. The transcription factor PLZF directs the effector program of the NKT cell lineage. Immunity 2008; 29:391-403.
9. Kovalovsky D, Uche OU, Eladad S, Hobbs RM, Yi W, Alonzo E, et al. The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nat Immunol 2008; 9:1055-64.
10. Costoya JA, Hobbs RM, Barna M, Cattoretti G, Manova K, Sukhwani M, et al. Essential role of Plzf in maintenance of spermatogonial stem cells. Nat Genet 2004; 36:653-9. (Pubitemid 38715996)
11. Hobbs R, Pandolfi P. Shape-shifting and tumor suppression by PLZF. Oncotarget 2010; 1:3-5.
12. Cheung M, Pei J, Pei Y, Jhanwar SC, Pass HI, Testa JR. The promyelocytic leukemia zinc-finger gene, PLZF, is frequently downregulated in malignant mesothelioma cells and contributes to cell survival. Oncogene 2010; 29:1633-40.
13. Rice KL, Hormaeche I, Doulatov S, Flatow JM, Grimwade D, Mills KI, et al. Comprehensive genomic screens identify a role for PLZF-RARalpha as a positive regulator of cell proliferation via direct regulation of c-MYC. Blood 2009; 114:5499-511.
14. McConnell MJ, Chevallier N, Berkofsky-Fessler W, Giltnane JM, Malani RB, Staudt LM, et al. Growth suppression by acute promyelocytic leukemia-associated protein PLZF is mediated by repression of c-myc expression. Mol Cell Biol 2003; 23:9375-88. (Pubitemid 37499823)
15. Hobbs RM, Seandel M, Falciatori I, Rafii S, Pandolfi PP. Plzf regulates germline progenitor self-renewal by opposing mTORC1. Cell 2010; 142:468-79.
16. Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 2004; 18:2893-904. (Pubitemid 39602308)
17. Ellisen LW, Ramsayer KD, Johannessen CM, Yang A, Beppu H, Minda K, et al. REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell 2002; 10:995-1005. (Pubitemid 35453821)
18. Shoshani T, Faerman A, Mett I, Zelin E, Tenne T, Gorodin S, et al. Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol Cell Biol 2002; 22:2283-93. (Pubitemid 34224633)
19. Pollard TD, Cooper JA. Actin, a central player in cell shape and movement. Science 2009; 326:1208-12.
20. Shi J, Sun M, Vogt PK. Smooth muscle alpha-actin is a direct target of PLZF: effects on the cytoskeleton and on susceptibility to oncogenic transformation. Oncotarget 2010; 1:9-21.
21. Dibble CC, Asara JM, Manning BD. Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol 2009; 29:5657-70.
22. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118:3065-74.
23. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004; 166:213-23. (Pubitemid 38988774)
24. Hartley D, Cooper GM. Role of mTOR in the degradation of IRS-1: regulation of PP2A activity. J Cell Biochem 2002; 85:304-14. (Pubitemid 34274898)
25. Haruta T, Uno T, Kawahara J, Takano A, Egawa K, Sharma PM, et al. A rapamycin-sensitive pathway downregulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol 2000; 14:783-94. (Pubitemid 32260492)
26. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008; 5:8.
27. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007; 26:1932-40. (Pubitemid 46474636)
28. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66:1500-8. (Pubitemid 43259931)
29. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65:7052-8. (Pubitemid 41161231)
30. Fumarola C, La Monica S, Alfieri RR, Borra E, Guidotti GG. Cell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosis. Cell Death Differ 2005; 12:1344-57. (Pubitemid 41486104)
31. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12:21-35.
32. Shor B, Gibbons JJ, Abraham RT, Yu K. Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle 2009; 8:3831-7.
33. Choo AY, Blenis J. Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle 2009; 8:567-72.
34. Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007; 13:3109-14. (Pubitemid 46944891)
35. Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, et al. Rapamycin extends maximal lifespan in cancer-prone mice. Am J Pathol 2010; 176:2092-7.
36. Bjedov I, Toivonen JM, Kerr F, Slack C, Jacobson J, Foley A, et al. Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. Cell Metab 2010; 11:35-46.
37. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009; 460:392-5.
38. Powers RW, 3rd, Kaeberlein M, Caldwell SD, Kennedy BK, Fields S. Extension of chronological life span in yeast by decreased TOR pathway signaling. Genes Dev 2006; 20:174-84.
39. Blagosklonny MV. Revisiting the antagonistic pleiotropy theory of aging: TOR-driven program and quasi-program. Cell Cycle 2010; 9:3151-6.
40. Schwarzer R, Tondera D, Arnold W, Giese K, Klippel A, Kaufmann J. REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase. Oncogene 2005; 24:1138-49. (Pubitemid 40313916)
41. Chang B, Liu G, Yang G, Mercado-Uribe I, Huang M, Liu J. REDD1 is required for RAS-mediated transformation of human ovarian epithelial cells. Cell Cycle 2009; 8:780-6.
42. Saucedo LJ, Gao X, Chiarelli DA, Li L, Pan D, Edgar BA. Rheb promotes cell growth as a component of the insulin/TOR signalling network. Nat Cell Biol 2003; 5:566-71.
43. Stocker H, Radimerski T, Schindelholz B, Wittwer F, Belawat P, Daram P, et al. Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nat Cell Biol 2003; 5:559-65. (Pubitemid 36781091)
44. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002; 4:648-57. (Pubitemid 34993700)
45. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 2002; 10:151-62. (Pubitemid 34876569)
46. Denne M, Sauter M, Armbruester V, Licht JD, Roemer K, Mueller-Lantzsch N. Physical and functional interactions of human endogenous retrovirus proteins Np9 and rec with the promyelocytic leukemia zinc finger protein. J Virol 2007; 81:5607-16. (Pubitemid 46847000)
47. van Dam H, Castellazzi M. Distinct roles of Jun: Fos and Jun: ATF dimers in oncogenesis. Oncogene 2001; 20:2453-64. (Pubitemid 32531302)
48. Parrado A, Robledo M, Moya-Quiles MR, Marin LA, Chomienne C, Padua RA, et al. The promyelocytic leukemia zinc finger protein downregulates apoptosis and expression of the proapoptotic BID protein in lymphocytes. Proc Natl Acad Sci USA 2004; 101:1898-903. (Pubitemid 38228988)
49. Yeyati PL, Shaknovich R, Boterashvili S, Li J, Ball HJ, Waxman S, et al. Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A. Oncogene 1999; 18:925-34. (Pubitemid 29086269)
50. Petrie K, Guidez F, Zhu J, Howell L, Owen G, Chew YP, et al. Retinoblastoma protein and the leukemia-associated PLZF transcription factor interact to repress target gene promoters. Oncogene 2008; 27:5260-6.
51. Guidez F, Parks S, Wong H, Jovanovic JV, Mays A, Gilkes AF, et al. RARalpha-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia. Proc Natl Acad Sci USA 2007; 104:18694-9. (Pubitemid 350210759)
52. Ivins S, Pemberton K, Guidez F, Howell L, Krumlauf R, Zelent A. Regulation of Hoxb2 by APL-associated PLZF protein. Oncogene 2003; 22:3685-97. (Pubitemid 36760731)
53. Barna M, Merghoub T, Costoya JA, Ruggero D, Branford M, Bergia A, et al. Plzf mediates transcriptional repression of HoxD gene expression through chromatin remodeling. Dev Cell 2002; 3:499-510. (Pubitemid 35256063)
54. Filipponi D, Hobbs RM, Ottolenghi S, Rossi P, Jannini EA, Pandolfi PP, et al. Repression of kit expression by Plzf in germ cells. Mol Cell Biol 2007; 27:6770-81. (Pubitemid 47483628)
55. Labbaye C, Spinello I, Quaranta MT, Pelosi E, Pasquini L, Petrucci E, et al. A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis. Nat Cell Biol 2008; 10:788-801. (Pubitemid 351927708)
56. Felicetti F, Errico MC, Bottero L, Segnalini P, Stoppacciaro A, Biffoni M, et al. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res 2008; 68:2745-54. (Pubitemid 351556272)
57. Schefe JH, Menk M, Reinemund J, Effertz K, Hobbs RM, Pandolfi PP, et al. A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res 2006; 99:1355-66. (Pubitemid 44949671)
58. Quaranta MT, Spinello I, Testa U, Mariani G, Diverio D, Foa R, et al. PLZF-mediated control on VLA-4 expression in normal and leukemic myeloid cells. Oncogene 2006; 25:399-408. (Pubitemid 43117625)